Independent Australian research guide · Updated 17 November 2026
GLP‑1s, without the hype.
How much weight do people actually lose? What causes plateaus? What are the risks—and what will a year of treatment cost in Australia? Trial data, dose-by-dose prices and calculators in one place.
Australian pricesPrimary research52-week costNot medical advice
$249.99Lowest listed Wegovy injection pen price / four weeks
13Four-week periods in 52 weeks—not 12
01 · The overview
What the science actually supports.
Prices: Nov 2026
GLP-1-based medicines can produce substantial weight loss for eligible patients, particularly alongside nutrition and movement changes. They reduce appetite and alter satiety signalling. Tirzepatide also acts on GIP receptors. They are not a substitute for diet quality, resistance training or long-term maintenance planning.
Australian publication warning. Prescription-only GLP-1 medicines cannot be advertised to the public in Australia. This is a factual, non-promotional reference page, with no product sales, booking links or endorsements. The TGA decides whether content amounts to advertising based on its overall effect; an educational disclaimer does not guarantee compliance. Obtain Australian legal/regulatory review before publishing an SEO-targeted brand-and-price comparison. TGA guidance ↗
Three realities
Different study ≠ direct comparison
Trial populations, diabetes status, doses, treatment duration and handling of dropouts vary. Use SURMOUNT-5 for the clearest tirzepatide-versus-semaglutide comparison.
Long-term view
Stopping often means regain
A 2026 meta-analysis found substantial weight regain during the year after GLP‑1 treatment cessation. Budget and plan for maintenance—not just the first few months.
02 · Science update
The important findings in 2025–2026.
Direct trial · 2025
One medicine did better head to head
In SURMOUNT‑5, people without diabetes averaged 20.2% loss on tirzepatide versus 13.7% on semaglutide at 72 weeks, on the studied doses and with lifestyle support. This is a group average, not a prediction.
STEP UP found 18.7% average loss with 7.2 mg versus 15.6% with 2.4 mg at 72 weeks under its primary treatment-policy analysis. Gastrointestinal effects were more frequent at 7.2 mg. It requires three 2.4 mg injections weekly in Australia.
Australia registered semaglutide tablets in 1.5, 4, 9 and 25 mg strengths on 3 November 2026. OASIS 4 found 13.6% mean loss at 64 weeks on 25 mg. No verified Chemist Warehouse retail price was available for this guide.
In a 40-week tirzepatide trial, three weekly resistance sessions reduced lean-tissue loss and improved strength despite similar total weight loss. The goal should not be merely a smaller number on the scales.
Average percentage loss in adults without diabetes. These studies are not directly comparable; trial times and methods differ.
Tirzepatide 15 mg
20.9%
Sema 7.2 mg
18.7%
Sema 2.4 mg
14.9%
Oral sema 25 mg
13.6%
Liraglutide 3 mg
~8%
SOURCES: SURMOUNT-1 (72 weeks), STEP UP (72 weeks), STEP 1 (68 weeks), OASIS 4 (64 weeks), SCALE (56 weeks). Values use the main published treatment-policy estimates where available; different trial designs mean a ranking is not scientifically valid.
Research figure on metabolic and cardiovascular GLP‑1 pathways. Zhao X and colleagues, licensed CC BY 4.0, via Wikimedia Commons. Displayed unchanged.03 · Interactive tool
Expected weight change, based on your starting weight.
Enter your starting weight. The calculator translates published trial-group averages into kilograms. It cannot reliably predict your individual result, and the effects shown are at the trial endpoint—not after 12 months.
Trial-group mean loss20.9%72 weeks
Translated into kilograms23.0 kgMathematical conversion only
Implied final weight87.0 kgNot an individual forecast
What various percentages would mean for you
This does not adjust for diabetes, age, sex, dose tolerance, treatment interruptions, adherence, baseline BMI or other medicines. Absolute kilogram figures are just starting weight × published percentage; they are not probability ranges. Do not use this calculator to choose a dose.
04 · Medicine comparison
The Australian options, without confusing the brands.
TGA weight-management indication
Wegovy (semaglutide)
Weekly injection: 0.25, 0.5, 1, 1.7 and 2.4 mg pens; certain adults may receive 7.2 mg as three 2.4 mg injections per week after escalation. New daily tablets: 1.5, 4, 9 and 25 mg, with retail pricing not verified.
TGA weight-management indication
Mounjaro (tirzepatide)
Weekly dual GIP/GLP-1 medicine. Six strengths from 2.5 to 15 mg. Usual maintenance options include 5, 10 and 15 mg; escalation is gradual. It has separate indications including type 2 diabetes and certain obesity-related sleep apnoea cases.
TGA weight-management indication
ARX-Liraglutide
Daily injection; generic liraglutide at a 3 mg daily maintenance dose. Usually slower and more modest weight loss than newer weekly drugs in historical trials. The older brand Saxenda was withdrawn from sale in Australia after December 2025.
Diabetes indication only
Ozempic and other diabetes brands
Ozempic contains semaglutide but is registered for type 2 diabetes, not chronic weight management. Its PBS price is only for eligible diabetes prescriptions. Rybelsus, Trulicity and Victoza are other diabetes products, not substitutes for an obesity treatment recommendation.
No GLP‑1 medicine in this guide is covered by the general PBS for weight management as of the November 2026 status check. Ozempic PBS subsidies for eligible type 2 diabetes are not available simply because somebody wants weight loss. Availability is pharmacy- and prescription-dependent.
05 · Price database
Chemist Warehouse prices, by brand and dose.
Australian dollars; private prescription where listed. Retail prices cross-checked against individual Chemist Warehouse product pages and a 9 November 2026 price review. These figures are not live quotations. Some pages show PBS pricing by default; the Ozempic prices below are its reported private price, not the subsidised PBS price.
Wegovy/Mounjaro injection packs each cover four weekly doses, so a 52-week year requires 13 periods. Wegovy 7.2 mg is calculated at three times the listed 2.4 mg pen price. ARX-Liraglutide is priced per five-pen pack (90 mg), not per fixed four-week month. No price is invented for products not sold or not listed. All brand and dose information should be checked against the current Australian Product Information before prescribing.
06 · Interactive tool
What will 52 weeks cost?
Choose a product and hypothetical prescribed maintenance target. The first-year calculation includes standard four-week escalation steps, without assuming delays, wastage or changes in dose. It is a cost illustration, not a titration instruction.
First 52 weeks · medication$4,449.8713 four-week pens
52 weeks at stable maintenance$4,809.87Maintenance-only comparison
First 52 weeks + optional fees$4,449.87Excludes supplies / travel
Earlier titrationMaintenanceEach tile is four weeks, unless noted
Period
Pack or dose
Cost
Estimates assume perfect dose continuity and purchasing full packs at listed prices. Dose changes and interruptions alter costs. For liraglutide, whole-pack estimates use drug quantity and do not account for expiry or wastage. Ozempic is included as a diabetes-only price illustration and not as an obesity treatment guide. Clinic, needle, sharps and delivery costs are excluded unless added above.
07 · Better outcomes
How to get more value from treatment.
There is no validated trick that guarantees maximum weight loss. The sensible objective is effective and sustainable fat loss without avoidable muscle loss, nutrient deficiency or side effects. These principles are supported by lifestyle guidelines and emerging GLP‑1-specific trials.
Protect function, not just scale weight
Keep regular meals nutrient-dense. Appetite suppression can make total food and protein intake too low; consider an accredited practising dietitian.
Do resistance training. Two or more days weekly is a sensible minimum where medically suitable; a 2026 trial used three days per week.
Get enough protein. Needs depend on weight, kidneys, age and activity; the 2026 Australian consensus suggests roughly 1.2–1.6 g/kg/day or 80–120 g/day when appropriate, individualised by a clinician.
Move consistently and sleep adequately. Walking, aerobic exercise, recovery and sleep support adherence and health.
Work with your prescriber on dose tolerance. A higher dose is not automatically safer or better, and should not be self-adjusted.
More weight loss is not always a better outcome. Pushing food intake too low or escalating doses without review can increase nausea, dehydration, constipation, loss of muscle mass and nutritional problems.
08 · What to do when progress slows
Plateauing is physiology, not necessarily failure.
As weight falls, the body generally uses less energy; the calorie gap narrows. Appetite, daily movement, energy expenditure, food intake and treatment adherence can change. A 2026 modelling study described plateaus even with continued therapy. A plateau can also reflect fluid fluctuations or constipation rather than stalled fat loss.
2–3 weeks of little movement
May be ordinary scale noise. Look at multi-week trends, weigh under similar conditions and consider changes in bowel habits.
4–8 weeks
Reassess weight trend, diet quality, portions, activity, resistance exercise, sleep and dose adherence with your care team.
Persistent plateau
Ask your prescriber whether your medication plan, related conditions, competing medicines or sustainable goals warrant review.
Your trend, not just one weigh-in
A simple reflection tool, not a medical definition or diagnosis of plateau. Weight fluctuation and measurement conditions matter. Do not change prescribed doses on the basis of this tool.
Six common reasons a plateau looks worse than it is
Smaller bodies usually expend fewer calories.
Day-to-day water retention masks changes in body fat.
Constipation adds scale weight and discomfort.
Food choices drift when initial appetite suppression feels less dramatic.
Reduced spontaneous movement offsets some dietary change.
A person has reached a sustainable new balance, even though the target weight is lower.
09 · Safety
Side effects, pitfalls and warning signs.
Common / often dose-related
Gastrointestinal effects
Nausea, vomiting, diarrhoea, constipation, reflux, abdominal discomfort and reduced appetite are common, especially after starting or increasing a dose. Hydration and tolerable meals matter. Report persistent or severe symptoms rather than simply pushing through.
Potentially serious
When to seek medical assessment
Persistent severe abdominal pain (including pain radiating to the back), ongoing vomiting or inability to keep fluids down, signs of dehydration, severe allergic symptoms, or sudden significant vision changes require prompt assessment. These medicines can be associated with gallbladder problems and pancreatitis.
Surgery / sedation
Tell the anaesthetist
GLP‑1 therapies delay gastric emptying and may increase the risk of stomach contents entering the lungs during anaesthesia or deep sedation. Inform your procedural team about all doses; follow their individual instructions.
These medicines should not be used during pregnancy. Semaglutide should be stopped at least two months before planned pregnancy, under medical guidance. Tirzepatide may reduce the reliability of oral hormonal contraception: the TGA advises non-oral contraception or an additional barrier for four weeks after starting and each dose increase.
Additional clinical considerations: hypoglycaemia risk increases when some GLP-1 medicines are combined with insulin or sulfonylureas; diabetes-related eye disease, prior pancreatitis, severe gastroparesis, kidney problems, eating disorder risk, other medicines and personal history all matter. Read the medicine-specific Australian Product Information and discuss risks with your clinician.
10 · The long-term question
What happens when treatment ends?
~60%
of lost weight regained, on average, during the year after stopping in a 2026 pooled analysis.
Based on six randomised trials used for nonlinear meta-regression (3,236 participants), within a wider systematic review. Individual results vary; long-term projections carry uncertainty.
Plan maintenance before stopping
Weight maintenance may require sustained treatment, ongoing dietary and physical activity support, and regular follow-up. Don't stop prescribed medicine solely because a target weight has been reached without discussing a maintenance plan.
Which GLP-1 medication produces the most weight loss?
In SURMOUNT-5, tirzepatide averaged 20.2% weight loss versus 13.7% for semaglutide over 72 weeks. Other higher-dose trial results come from different populations and cannot be directly ranked as if they were a single trial.
How much does Mounjaro cost at Chemist Warehouse?
Listed private prices checked against Chemist Warehouse in November 2026 ranged from $279.99 for 2.5 mg to $689.99 for 12.5 mg or 15 mg per four-dose pen. Prices can change.
How much does Wegovy cost per year in Australia?
At the checked private prices, 52 weeks following the usual dose escalation to 2.4 mg costs $4,449.87 for 13 four-week pens. A full maintenance year at 2.4 mg costs $4,809.87, excluding clinical fees.
Why does weight loss plateau on GLP-1 drugs?
The body becomes lighter and expends less energy. Eventually energy intake and expenditure may balance at a new weight. Slower loss is expected and does not automatically mean the medicine has stopped working.
Will I regain weight if I stop?
Regain is common. A 2026 meta-analysis estimated that about 60% of the weight lost was regained within one year after GLP-1 treatment stopped, across the included randomised trials.
Is Ozempic approved for weight loss in Australia?
No. Ozempic is registered for type 2 diabetes; Wegovy is a semaglutide product registered for chronic weight management. PBS access for Ozempic is subject to diabetes eligibility rules.
Are Wegovy tablets available in Australia?
Wegovy tablets in 1.5 mg, 4 mg, 9 mg and 25 mg strengths were registered in Australia on 3 November 2026. A confirmed Chemist Warehouse selling price was not found at the date of this guide.
12 · Evidence transparency
Sources and editorial notes.
All factual claims are intended to be traceable to trials, Australian regulators, guidelines or pharmacy listings. Retail prices were checked in November 2026 and may change without notice. This guide is not sponsored by, endorsed by or affiliated with Chemist Warehouse or any drug manufacturer.